Gain Therapeutics (GANX)
(Real Time Quote from BATS)
$1.13 USD
+0.08 (7.62%)
Updated Sep 9, 2024 01:10 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
GANX 1.13 +0.08(7.62%)
Will GANX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GANX
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Other News for GANX
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Gain Therapeutics announces reuslts from Phase 1 study of GT-02287
Gain slips after early-stage data for Parkinson’s therapy
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson?s Disease
Gain Therapeutics assumed with an Outperform at Oppenheimer